The results of our study demonstrated that Fraction B has potent antitumor activity in pancreatic cancer, mainly through inhibiting pancreatic CSC marker CD44 expression and altering critical tumor cell metabolic pathways with no, or very limited systemic toxicity, suggesting the high translational value of Fraction B for pancreatic cancer therapy. This evidence concerns the gene CD44 and familial pancreatic carcinoma.